<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286871</url>
  </required_header>
  <id_info>
    <org_study_id>6538</org_study_id>
    <secondary_id>6538-04-11R0</secondary_id>
    <nct_id>NCT00286871</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen</brief_title>
  <official_title>Steroid Avoidance in Hep C OLT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      Liver transplant subjects will be given Mycophenolate (MMF) and Tacrolimus in order to help
      prevent post-transplant rejection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent HCV in the liver allograft is becoming the leading indicator for retransplantation.
      Studies suggest that glucocorticord-based immunosuppression regimens hasten the onset and
      progression of recurrent chronic HCV liver disease. Treatment of acute allograft rejection
      with steroid boluses is also associated with rapid HCV recurrence. The relative contribution
      of various calcineurin inhibitors to recurrent HCV liver disease has not been established.
      Previous retrospective studies, as well as prospective studies have not demonstrated a
      difference in recurrent HCV liver disease rates between patients receiving CsA or tacrolimus
      immunosuppression regimens respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date>February 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare timing &amp; severity of recurrent chronic HCV disease Neoral versus Prograf</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare the effectiveness of Neoral with Prograf as primary immunotherapy</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Organ Transplantation</condition>
  <condition>Immunosuppression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoral</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients who have received liver transplant

        Exclusion Criteria:

          -  pregnant women

          -  nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devai Desai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996 Mar 28;334(13):815-20.</citation>
    <PMID>8596547</PMID>
  </reference>
  <reference>
    <citation>Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, Juan FS, López-Labrador FX, Moreno R, Mir J, Berenguer J. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl. 2003 Mar;9(3):228-35.</citation>
    <PMID>12619018</PMID>
  </reference>
  <reference>
    <citation>McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl. 2002 Oct;8(10 Suppl 1):S7-S13. Review.</citation>
    <PMID>12362292</PMID>
  </reference>
  <reference>
    <citation>Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, Pinna AD, Kato T, Miller J, Reddy KR, Tzakis AG. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. Transplant Proc. 1998 Jun;30(4):1405-6.</citation>
    <PMID>9636568</PMID>
  </reference>
  <reference>
    <citation>Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl. 2001 Aug;7(8):693-7.</citation>
    <PMID>11510013</PMID>
  </reference>
  <reference>
    <citation>Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981 Sep-Oct;1(5):431-5.</citation>
    <PMID>7308988</PMID>
  </reference>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

